436 related articles for article (PubMed ID: 23622774)
1. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
3. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
[TBL] [Abstract][Full Text] [Related]
4. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
Goodman OB; Fink LM; Symanowski JT; Wong B; Grobaski B; Pomerantz D; Ma Y; Ward DC; Vogelzang NJ
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1904-13. PubMed ID: 19505924
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
8. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Aragon-Ching JB; Siegel RS; Frazier H; Andrawis R; Hendricks F; Phillips M; Jarrett T; Guebre-Xabiher H; Patierno S; Simmens SJ
Clin Genitourin Cancer; 2015 Oct; 13(5):e341-5. PubMed ID: 25956468
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the enumeration and phenotyping of CTC.
Coumans FA; Ligthart ST; Uhr JW; Terstappen LW
Clin Cancer Res; 2012 Oct; 18(20):5711-8. PubMed ID: 23014524
[TBL] [Abstract][Full Text] [Related]
11. Analogous detection of circulating tumor cells using the AccuCyte
van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
[TBL] [Abstract][Full Text] [Related]
12. Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer.
Todenhöfer T; Park ES; Duffy S; Deng X; Jin C; Abdi H; Ma H; Black PC
Urol Oncol; 2016 Nov; 34(11):483.e9-483.e16. PubMed ID: 27658563
[TBL] [Abstract][Full Text] [Related]
13. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy.
Lowes LE; Lock M; Rodrigues G; D'Souza D; Bauman G; Ahmad B; Venkatesan V; Allan AL; Sexton T
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):358-64. PubMed ID: 26238233
[TBL] [Abstract][Full Text] [Related]
14. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
[No Abstract] [Full Text] [Related]
15. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
Giridhar KV; Sanhueza C; Hillman DW; Alkhateeb H; Carlson R; Tan W; Costello BA; Quevedo F; Pagliaro L; Kohli M
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):431-437. PubMed ID: 29858590
[TBL] [Abstract][Full Text] [Related]
16. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform.
Guo W; Yang XR; Sun YF; Shen MN; Ma XL; Wu J; Zhang CY; Zhou Y; Xu Y; Hu B; Zhang X; Zhou J; Fan J
Clin Cancer Res; 2014 Sep; 20(18):4794-805. PubMed ID: 25009297
[TBL] [Abstract][Full Text] [Related]
18. The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.
de Wit S; van Dalum G; Lenferink AT; Tibbe AG; Hiltermann TJ; Groen HJ; van Rijn CJ; Terstappen LW
Sci Rep; 2015 Jul; 5():12270. PubMed ID: 26184843
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.
Resel Folkersma L; San José Manso L; Galante Romo I; Moreno Sierra J; Olivier Gómez C
Urology; 2012 Dec; 80(6):1328-32. PubMed ID: 23063057
[TBL] [Abstract][Full Text] [Related]
20. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]